Breast Cancer

The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast cancer are pushing the needle forward in making this breast cancer subtype a chronic disease.

Aditya Bardia, MD, MPH, discusses efficacy with atezolizumab combinations in patients with metastatic triple-negative breast cancer.

Mei Wei, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer, as demonstrated in the DESTINY-Breast01 trial.

The FDA has issued a complete response letter to Athenex, Inc. stating that it will not, at this time, approve the new drug application for oral paclitaxel in combination with encequidar for the treatment of patients with metastatic breast cancer.

Sara A. Hurvitz, MD, discusses the potential integration of oral taxanes into the treatment paradigm of patients with metastatic breast cancer.

Christos Vaklavas, MD, discusses the progress that has been made in metastatic HR-positive, HER2-negative breast cancer and potential pathways forward for therapeutic sequencing.

February 17, 2021 - An independent data monitoring committee has concluded that the phase 3 OlympiA trial examining olaparib crossed the superiority boundary for its primary end point of invasive disease-free survival in patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer.

Dr. Schilsky highlights key milestones in his career with ASCO, Dr. Gralow speaks to the short- and long-term goals she plans to accomplish in her new role at ASCO, and both speak to their thoughts on the future of cancer care.

John Marshall, MD, and his wife, Liza, recount the challenging journey of Liza's triple-negative breast cancer (TNBC) diagnosis and how John's career as a gastrointestinal oncologist played into the caregiving process. The interview comes ahead of the release of their book, Off Our Chests, which goes further in depth with their experience.

February 12, 2021 - The European Commission has granted marketing authorization to tucatinib for use in combination with trastuzumab and capecitabine in the treatment of adult patients with HER2-positive, locally advanced or metastatic breast cancer who have previously received at least 2 HER2-targeted regimens

Dennis J. Slamon, MD, PhD, discusses how his passion for medicine stemmed from a high school biology class, the struggle to develop trastuzumab as a viable drug in HER2-positive breast cancer, and the movie about his research that he didn’t want to see made.